Eli Lilly has become one of the most strategically important pharmaceutical companies in the world, driven by its leadership in diabetes and obesity medicines, alongside growing activity in oncology, immunology, neuroscience, and rare disease.
Read More
Eisai is an established healthcare institution whose principal relevance to this ranking lies in neurology, oncology and global prescription medicines. Its inclusion reflects an operating platform that is active, institutionally visible, and sufficiently developed to be assessed alongside other consequential participants in global Pharmaceutical Companies.
Read More
Editas Medicine is a gene editing company founded around CRISPR technology and has been active in ocular disease, hematology, and inherited disorders. Although the company has faced strategic shifts and competitive pressure, it remains a recognizable developer in the gene editing ecosystem.
Read More
Dyne Therapeutics is an established healthcare institution whose principal relevance to this ranking lies in muscle-targeted oligonucleotide therapies for rare neuromuscular diseases. Its inclusion reflects an operating platform that is active, institutionally visible, and sufficiently developed to be assessed alongside other consequential participants in rare Disease & Orphan Drug Developers.
Read More
Dynavax Technologies is a vaccine-focused biopharmaceutical company whose principal relevance to this ranking lies in adjuvanted vaccines and immune-stimulation technology. Its inclusion reflects an operating platform that is active, institutionally visible, and sufficiently developed to be assessed alongside other consequential participants in vaccine & Immunotherapy Developers.
Read More
Delpharm is a contract development and manufacturing organization (CDMO) whose principal relevance to this ranking lies in European pharmaceutical development and contract manufacturing. Its inclusion reflects an operating platform that is active, institutionally visible, and sufficiently developed to be assessed alongside other consequential participants in biomanufacturing & CDMO Providers.
Read More
Daiichi Sankyo is an established healthcare institution whose principal relevance to this ranking lies in global pharmaceutical companies. Its inclusion reflects an operating platform that is active, institutionally visible, and sufficiently developed to be assessed alongside other consequential participants in global Pharmaceutical Companies.
Read More
Curia Global is a contract research, development and manufacturing organization (CDMO) whose principal relevance to this ranking lies in drug discovery, development and commercial manufacturing. Its inclusion reflects an operating platform that is active, institutionally visible, and sufficiently developed to be assessed alongside other consequential participants in biomanufacturing & CDMO Providers.
Read More
CureVac is an established healthcare institution whose principal relevance to this ranking lies in vaccine & immunotherapy developers. Its inclusion reflects an operating platform that is active, institutionally visible, and sufficiently developed to be assessed alongside other consequential participants in vaccine & Immunotherapy Developers.
Read More
CSL is a global biotechnology group supplying biotherapies, plasma products, influenza vaccines, and iron and nephrology medicines through CSL Behring, CSL Seqirus and CSL Vifor. Its origins date to 1916; CSL Limited was incorporated in 1991 and listed on the ASX in 1994.
Read More
CSL Seqirus is one of the world’s most important influenza vaccine developers and manufacturers. As part of CSL, the business benefits from biologics manufacturing expertise, global public health relationships, and strong experience in seasonal and pandemic influenza vaccine supply.
Read More
CSL Behring is one of the world’s leading specialty biologics companies, focused on plasma-derived therapies, immunoglobulins, hemophilia, hereditary angioedema, immunology, and rare diseases. Its business model is highly specialized, combining biologic manufacturing, plasma collection, global distribution, and specialist medicine.
Read More
CRISPR Therapeutics is one of the most important gene editing companies globally. Its partnership with Vertex on Casgevy established CRISPR editing as an approved therapeutic modality and marked one of the most important milestones in the history of genetic medicine.
Read More
CordenPharma is a contract development and manufacturing organization (CDMO) whose principal relevance to this ranking lies in integrated development and manufacturing for complex modalities. Its inclusion reflects an operating platform that is active, institutionally visible, and sufficiently developed to be assessed alongside other consequential participants in biomanufacturing & CDMO Providers.
Read More
Corcept Therapeutics is an established healthcare institution whose principal relevance to this ranking lies in cortisol-modulation medicines and endocrine disease. Its inclusion reflects an operating platform that is active, institutionally visible, and sufficiently developed to be assessed alongside other consequential participants in specialty Pharma Companies.
Read More
Collegium Pharmaceutical is an established healthcare institution whose principal relevance to this ranking lies in specialty pain-management medicines. Its inclusion reflects an operating platform that is active, institutionally visible, and sufficiently developed to be assessed alongside other consequential participants in specialty Pharma Companies.
Read More
ClinChoice is an established healthcare institution whose principal relevance to this ranking lies in global clinical development, functional services and data operations. Its inclusion reflects an operating platform that is active, institutionally visible, and sufficiently developed to be assessed alongside other consequential participants in contract Research Organizations.
Read More
Clario is a clinical trial technology and endpoint services company supporting pharmaceutical and biotechnology sponsors through electronic clinical outcome assessments, cardiac safety, medical imaging, respiratory endpoints, and trial data solutions.
Read More
Chugai Pharmaceutical is an established healthcare institution whose principal relevance to this ranking lies in antibody engineering, oncology and specialty medicines. Its inclusion reflects an operating platform that is active, institutionally visible, and sufficiently developed to be assessed alongside other consequential participants in global Pharmaceutical Companies.
Read More
Chiesi Global Rare Diseases is a focused rare disease platform within Chiesi Group. It develops and commercializes therapies for rare metabolic, lysosomal storage, and specialty conditions, with a growing international presence in orphan disease markets.
Read More